Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gyroscope Merger Creates Gene Therapy Biotech For Eye Disorders

Executive Summary

A new UK/US biotech tie-up makes a company with the technology to deliver its gene therapies.

You may also be interested in...



Gyroscope Targeting ‘Huge’ Population With Dry AMD Gene Therapy

Bringing gene therapy to the masses: company raises extra £50m in series B fundraising for novel dry macular degeneration treatment

Pipeline Watch: Top-Line Phase III Results With Filgotinib, Bavencio/Inlyta, Zerbaxa

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Roche's Dry AMD Drug Lampalizumab Delivers Disappointment In Phase III

Analysts had already been doubtful about the prospects for success in the Spectri study. A second Phase III trial is ongoing, but the candidate is already being removed from revenue models.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125054

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel